<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>药智网 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-21T16:53:05+08:00</updated>
  <subtitle>一个有态度、有深度、有温度的医药健康领域融媒体平台。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>直播在即 | 儿科临床实验困难重重，究竟如何高效实施儿科临床研究？</title>
    <updated>2021-01-21T15:58:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-21:/s/IcAkEc0_sPDBbXp2Y6wOGA</id>
    <link href="https://mp.weixin.qq.com/s/IcAkEc0_sPDBbXp2Y6wOGA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>两会“药”声！医药圈代表、委员如何建言中医药？</title>
    <updated>2021-01-21T15:58:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-21:/s/XPt4QkRU_TuUamGQpt3aGQ</id>
    <link href="https://mp.weixin.qq.com/s/XPt4QkRU_TuUamGQpt3aGQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>中纪委连发两文直指医药腐败，超半数百强药企有回扣行为</title>
    <updated>2021-01-21T15:58:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-21:/s/TtBAzs1gbeT-z-t4tz15HA</id>
    <link href="https://mp.weixin.qq.com/s/TtBAzs1gbeT-z-t4tz15HA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>突发！顶级大三甲停诊</title>
    <updated>2021-01-21T15:58:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-21:/s/u4RphoQFRq_TLB7h5V-hGw</id>
    <link href="https://mp.weixin.qq.com/s/u4RphoQFRq_TLB7h5V-hGw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020盘点：专家回顾2020医保政策，看懂2021年政策走向！</title>
    <updated>2021-01-20T16:29:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-20:/s/yTaRunAQle6KZbi-uHelwQ</id>
    <link href="https://mp.weixin.qq.com/s/yTaRunAQle6KZbi-uHelwQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>千亿美元糖尿病用药市场，度拉鲁肽五年复合增长率124.2%</title>
    <updated>2021-01-20T16:29:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-20:/s/Zqwbe2jeeDJcAkJTKUrVlQ</id>
    <link href="https://mp.weixin.qq.com/s/Zqwbe2jeeDJcAkJTKUrVlQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>江苏药品集采结果出炉，最高降幅93%！</title>
    <updated>2021-01-20T16:29:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-20:/s/SNtyGR8uCyZCxq0EskqU_g</id>
    <link href="https://mp.weixin.qq.com/s/SNtyGR8uCyZCxq0EskqU_g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>药智学院MDP精英训练营 | 医药数据检索与研发立项专题培训</title>
    <updated>2021-01-20T16:29:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-20:/s/x-CjXWAR_pZQu1QiMB5hhA</id>
    <link href="https://mp.weixin.qq.com/s/x-CjXWAR_pZQu1QiMB5hhA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>“生物导弹”ADC 药物迎来黄金时代，挑战下一个千亿市场！</title>
    <updated>2021-01-19T17:16:39+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-19:/s/mP_BCPPPmd4nS2xhGl3AWg</id>
    <link href="https://mp.weixin.qq.com/s/mP_BCPPPmd4nS2xhGl3AWg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>32亿市场迎变局？第四批集采，辉瑞“独占三元”？</title>
    <updated>2021-01-19T17:16:39+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-19:/s/-uuiTS3iOpNQvaOk09kDrA</id>
    <link href="https://mp.weixin.qq.com/s/-uuiTS3iOpNQvaOk09kDrA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>第四批国采：总采购规模及“缩水”程度分析</title>
    <updated>2021-01-19T17:16:39+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-19:/s/fWnTDvT2y5-4VxIhLMgdJA</id>
    <link href="https://mp.weixin.qq.com/s/fWnTDvT2y5-4VxIhLMgdJA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>3000万元鼓励员工留下过年，这家药企为何如此豪气？</title>
    <updated>2021-01-19T17:16:39+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-19:/s/K8j9jhJfw-TUzQzoOwjqsg</id>
    <link href="https://mp.weixin.qq.com/s/K8j9jhJfw-TUzQzoOwjqsg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2021第一惊雷：基药目录调整或加速度！</title>
    <updated>2021-01-18T16:16:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-18:/s/CuZq7FAPmjpIZjhsem4Xtw</id>
    <link href="https://mp.weixin.qq.com/s/CuZq7FAPmjpIZjhsem4Xtw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020盘点：医药圈关键词TOP10！第7个实至名归！</title>
    <updated>2021-01-18T16:16:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-18:/s/O--xaJVmlWiCO3QaoEh8YA</id>
    <link href="https://mp.weixin.qq.com/s/O--xaJVmlWiCO3QaoEh8YA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>全球CDMO规模逼近千亿美元，新药研发推动CDMO快速发展</title>
    <updated>2021-01-18T16:16:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-18:/s/UYEMkmG1Kf0pHAGwaTPp2g</id>
    <link href="https://mp.weixin.qq.com/s/UYEMkmG1Kf0pHAGwaTPp2g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020年，299位药企高管离职（附名单）</title>
    <updated>2021-01-18T16:16:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-18:/s/SlN1PTOZEDsE380WwkXtcw</id>
    <link href="https://mp.weixin.qq.com/s/SlN1PTOZEDsE380WwkXtcw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【药咖君】复星凯特CAR-T上市在即！PD-1单抗适应症之争还在继续，百济神州、信达…</title>
    <updated>2021-01-17T10:06:13+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-17:/s/O0UhLJV3bnMrj4ScpZJXBQ</id>
    <link href="https://mp.weixin.qq.com/s/O0UhLJV3bnMrj4ScpZJXBQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>高层定调“药品集采常态化制度化”！2021将是十年以来真正的招标大年！</title>
    <updated>2021-01-15T23:40:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/tWh1kmToK4Jjhe0sILtnXg</id>
    <link href="https://mp.weixin.qq.com/s/tWh1kmToK4Jjhe0sILtnXg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>从0到180亿，谢良志和他的“重组蛋白药物王国”</title>
    <updated>2021-01-15T23:40:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/3oQjWyKM7GwthgFxEeAtuQ</id>
    <link href="https://mp.weixin.qq.com/s/3oQjWyKM7GwthgFxEeAtuQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>药品主战场仍是“小分子”，“Protac”或是赶超海外药企的关键</title>
    <updated>2021-01-15T16:40:39+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/zylf0f86B5B8HNxY810a1Q</id>
    <link href="https://mp.weixin.qq.com/s/zylf0f86B5B8HNxY810a1Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>